Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study

Bevacizumab has demonstrated significant benefit in recurrent ovarian, fallopian tube and peritoneal cancer (OC), but its optimal position within the sequence of systemic therapies remains controversial. Since rebound progression after bevacizumab has been observed in other cancers, and because beva...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghezelayagh, Talayeh S., Wu, Emily S., Barber, Emma L., Dao, Minh D., Zsiros, Emese, Urban, Renata R., Gray, Heidi J., Goff, Barbara A., Shah, Chirag A., Neubauer, Nikki L., Dai, James Y., Tanyi, Janos L., Liao, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980410/
https://www.ncbi.nlm.nih.gov/pubmed/36874058
http://dx.doi.org/10.22514/ejgo.2023.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980410/
https://www.ncbi.nlm.nih.gov/pubmed/36874058
http://dx.doi.org/10.22514/ejgo.2023.002

Ejemplares similares